ATE518835T1 - Kristallform einer chinolinverbindung und verfahren zu deren herstellung - Google Patents

Kristallform einer chinolinverbindung und verfahren zu deren herstellung

Info

Publication number
ATE518835T1
ATE518835T1 AT04807807T AT04807807T ATE518835T1 AT E518835 T1 ATE518835 T1 AT E518835T1 AT 04807807 T AT04807807 T AT 04807807T AT 04807807 T AT04807807 T AT 04807807T AT E518835 T1 ATE518835 T1 AT E518835T1
Authority
AT
Austria
Prior art keywords
crystal form
production
quinoline compound
stability
drug substance
Prior art date
Application number
AT04807807T
Other languages
English (en)
Inventor
Yoshio Ohara
Yasutaka Takada
Hiroo Matsumoto
Akihiro Yoshida
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34736450&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE518835(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Application granted granted Critical
Publication of ATE518835T1 publication Critical patent/ATE518835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04807807T 2003-12-26 2004-12-17 Kristallform einer chinolinverbindung und verfahren zu deren herstellung ATE518835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003431788 2003-12-26
PCT/JP2004/019451 WO2005063711A1 (en) 2003-12-26 2004-12-17 Crystal form of quinoline compound and process for its production

Publications (1)

Publication Number Publication Date
ATE518835T1 true ATE518835T1 (de) 2011-08-15

Family

ID=34736450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04807807T ATE518835T1 (de) 2003-12-26 2004-12-17 Kristallform einer chinolinverbindung und verfahren zu deren herstellung

Country Status (22)

Country Link
US (18) US20070112024A1 (de)
EP (1) EP1697326B1 (de)
JP (7) JP5186108B2 (de)
KR (11) KR20180132973A (de)
CN (2) CN102321019B (de)
AT (1) ATE518835T1 (de)
AU (2) AU2004309241A1 (de)
CA (1) CA2551050C (de)
CY (1) CY1112464T1 (de)
DK (1) DK1697326T3 (de)
ES (1) ES2367172T3 (de)
HK (1) HK1095328A1 (de)
IL (1) IL176470A (de)
MX (1) MX338019B (de)
NZ (1) NZ548041A (de)
PL (1) PL1697326T3 (de)
PT (1) PT1697326E (de)
RU (1) RU2370489C2 (de)
SI (1) SI1697326T1 (de)
TW (1) TWI328006B (de)
WO (1) WO2005063711A1 (de)
ZA (1) ZA200605658B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072040A1 (en) 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US7801272B2 (en) * 2007-09-28 2010-09-21 Rigaku Corporation X-ray diffraction apparatus and X-ray diffraction method
US20120022102A1 (en) 2010-01-20 2012-01-26 Cadila Healthcare Limited Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof
KR101158517B1 (ko) 2010-04-29 2012-06-21 동방에프티엘(주) 고 순도 피타바스타틴 칼슘염 결정형 ａ의 제조방법
US9034901B2 (en) 2010-08-25 2015-05-19 Cadila Healthcare Limited Pitavastatin calcium and process for its preparation
WO2012063254A1 (en) 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
RU2452939C1 (ru) * 2011-01-18 2012-06-10 Закрытое акционерное общество "Научные приборы" Рентгенодифракционный способ идентификации партий фармацевтической продукции
ITMI20111475A1 (it) * 2011-08-02 2013-02-03 Dipharma Francis Srl Forme cristalline di pitavastatina sale di calcio
PT2751081T (pt) * 2011-09-12 2017-04-04 D O O Farma Grs Forma polimórfica de pitavastatina cálcica
WO2013098773A1 (en) * 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Crystalline forms of pitavastatin calcium
KR101461841B1 (ko) 2012-08-08 2014-11-13 코와 가부시키가이샤 의약
IN2015DN03012A (de) * 2012-09-27 2015-10-02 Nissan Chemical Ind Ltd
JP2014034574A (ja) * 2013-01-25 2014-02-24 Kowa Company Ltd 医薬
AU2014232722B2 (en) 2013-03-15 2017-03-09 Jiangsu Yahong Meditech Co., Ltd. Base addition salts of nitroxoline and uses thereof
CN105213319A (zh) * 2015-09-17 2016-01-06 青岛华之草医药科技有限公司 一种降血脂药物匹伐他汀钙组合物干混悬剂
JP2016222714A (ja) * 2016-09-20 2016-12-28 興和株式会社 医薬
TW202200547A (zh) * 2020-03-13 2022-01-01 印度商卡地拉保健有限公司 喹啉酮化合物的新穎鹽類
KR20230159487A (ko) * 2021-03-19 2023-11-21 자이두스 라이프사이언시즈 리미티드 고체 형태의 퀴놀론 화합물 및 이의 제조 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3175944A (en) * 1956-06-18 1965-03-30 Upjohn Co Dihydronovobiocin and derivatives thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
GB8320521D0 (en) * 1983-07-29 1983-09-01 Glaxo Group Ltd Chemical process
JPS61171460A (ja) * 1985-01-23 1986-08-02 Dainippon Pharmaceut Co Ltd 塩酸メクロフエノキサ−ト１型結晶の製造法
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
JP2877366B2 (ja) 1988-08-25 1999-03-31 協和醗酵工業株式会社 結晶状ｌ−アスコルビン酸−２−リン酸ナトリウム塩の製造法
JP3528186B2 (ja) * 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
JPH0613526A (ja) 1992-06-25 1994-01-21 Seiko Epson Corp 半導体装置用リードフレーム及びその製造方法
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
FR2694558B1 (fr) 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
DE4235133A1 (de) 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
JP3623531B2 (ja) 1993-06-07 2005-02-23 ビーエーエスエフ アクチェンゲゼルシャフト 結晶質ｌ−アスコルビン酸−２−燐酸エステルマグネシウム塩の製造法
JP3558684B2 (ja) * 1994-06-28 2004-08-25 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の乾燥方法
CA2450820C (en) * 2001-08-16 2011-03-15 Teva Pharmaceutical Industries Ltd. Processes for preparing calcium salt forms of statins
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
DE60326819D1 (de) * 2002-01-31 2009-05-07 Novartis Ag Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP1496057A4 (de) * 2002-04-17 2006-05-03 Astellas Pharma Inc Neuer kristall von chinoxalindionderivatanhydrid
WO2004072040A1 (en) * 2003-02-12 2004-08-26 Ciba Specialty Chemicals Holding Inc. Crystalline forms of pitavastatin calcium
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production

Also Published As

Publication number Publication date
JP2013136640A (ja) 2013-07-11
JP5186108B2 (ja) 2013-04-17
US20140206719A1 (en) 2014-07-24
KR20160075844A (ko) 2016-06-29
WO2005063711A1 (en) 2005-07-14
AU2011213742C1 (en) 2017-04-06
CY1112464T1 (el) 2015-12-09
ZA200605658B (en) 2007-11-28
KR20130014643A (ko) 2013-02-07
US20180297956A1 (en) 2018-10-18
JP2014205719A (ja) 2014-10-30
IL176470A0 (en) 2006-10-05
US20210053923A1 (en) 2021-02-25
DK1697326T3 (da) 2011-09-19
KR20110017936A (ko) 2011-02-22
RU2006127044A (ru) 2008-02-10
JP2016029102A (ja) 2016-03-03
US20220177433A1 (en) 2022-06-09
CN102321019A (zh) 2012-01-18
US20110082298A1 (en) 2011-04-07
SI1697326T1 (sl) 2011-11-30
AU2011213742B2 (en) 2014-05-15
US20130204000A1 (en) 2013-08-08
RU2370489C2 (ru) 2009-10-20
MX338019B (es) 2016-03-29
IL176470A (en) 2011-10-31
US20180072676A1 (en) 2018-03-15
US20090176987A1 (en) 2009-07-09
JP2017061536A (ja) 2017-03-30
ES2367172T3 (es) 2011-10-31
US20190152916A1 (en) 2019-05-23
CN102321019B (zh) 2016-06-08
PT1697326E (pt) 2011-09-12
US20230322679A1 (en) 2023-10-12
KR20170098976A (ko) 2017-08-30
KR20180040732A (ko) 2018-04-20
CN1898211A (zh) 2007-01-17
AU2011213742A1 (en) 2011-09-08
AU2004309241A1 (en) 2005-07-14
KR20170010111A (ko) 2017-01-25
JP2012072175A (ja) 2012-04-12
KR20070001910A (ko) 2007-01-04
HK1095328A1 (en) 2007-05-04
US20150158816A1 (en) 2015-06-11
JP2018052988A (ja) 2018-04-05
TW200530186A (en) 2005-09-16
JP2007516952A (ja) 2007-06-28
US20070112024A1 (en) 2007-05-17
CA2551050A1 (en) 2005-07-14
KR20200015826A (ko) 2020-02-12
NZ548041A (en) 2010-04-30
KR20190083674A (ko) 2019-07-12
KR20180132973A (ko) 2018-12-12
US20170226061A1 (en) 2017-08-10
EP1697326A1 (de) 2006-09-06
US20200216395A1 (en) 2020-07-09
TWI328006B (en) 2010-08-01
US20120245200A1 (en) 2012-09-27
JP5267643B2 (ja) 2013-08-21
US20190367458A1 (en) 2019-12-05
US20110319624A1 (en) 2011-12-29
CA2551050C (en) 2020-06-02
US20140058109A1 (en) 2014-02-27
KR20200130510A (ko) 2020-11-18
PL1697326T3 (pl) 2011-12-30
EP1697326B1 (de) 2011-08-03

Similar Documents

Publication Publication Date Title
IL176470A0 (en) Crystal form of quinoline compound and process for its production
ATE240314T1 (de) Kristalle von benzimidazolderivate und verfahren zu ihrer herstellung
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
DE602004030239D1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
ATE506352T1 (de) Verfahren zur herstellung von optional 2- substituierten 1,6-dihydro-6-oxo-4- pyrimidincarboxylsäuren
ATE198197T1 (de) Benzimidazolderivate, verfahren zu deren herstellung und deren anwendung
RS20050182A (en) Derivatives of dioxane-2-alkyl carbamates,preparation method thereof and application of same in therapeutics
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
DK1751093T3 (da) Substituerede cyklohexyleddikesyre-derivater
ATE319702T1 (de) Verfahren zur herstellung von benzothiophen- derivaten
DE602004025344D1 (de) Biologisch abbaubare verzweigte polylactidderivate, die zur bildung von polymermicellen befähigt sind, herstellungsverfahren dafür und verwendung davon
MX2009010727A (es) Heterociclos como antagonistas de orexina.
HK1133001A1 (en) Novel method for producing 4,4'-(1-methyl-1,2-ethanediyl)-bis-(2,6- piperazinedione)
ATE386734T1 (de) Verfahren zur herstellung von (4-hydroxy-6-oxo- tetrahydropyran-2-yl) acetonitril und dessen derivaten
ATE466010T1 (de) Verfahren zur herstellung von candesartan
ATE415404T1 (de) Lösungsmittelfreies verfahren zur herstellung von diketopyrrolopyrrol-derivaten
DE602004030616D1 (de) Amlodipin-gentisat und verfahren zu dessen herstellung
FR2840900B1 (fr) Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments
DE60106778D1 (de) Verfahren zur herstellung von vitronectin-rezeptorantagonisten
DE602005013007D1 (de) Verfahren zur herstellung von lactonen
ATE270296T1 (de) Verfahren zur herstellung von hochkristallinem natrium cefoperazon
DE502004006253D1 (de) Substituierte benzoylureidopyridyl-piperidin- und -pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung
DE502004010108D1 (de) Carbonylamino-substituierte acyl-phenyl-harnstoffderivate, verfahren zu deren herstellung und deren verwendung
ATE309226T1 (de) Verfahren zur herstellung von fluconazole und kristallmodifikationen davon
ATE326447T1 (de) Chirale gerüste und deren herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1697326

Country of ref document: EP